Dr. Stuart H. Orkin is a renowned American physician-scientist whose decades of work in pediatric hematology and molecular genetics have helped transform the understanding and treatment of inherited blood disorders. Based in Boston, Massachusetts, he is the David G. Nathan Distinguished Professor of Pediatrics at Harvard Medical School, an investigator at Boston Children’s Hospital and Dana-Farber Cancer Institute, and a Howard Hughes Medical Institute investigator.
Dr. Orkin earned his bachelor’s degree from MIT and his medical degree from Harvard Medical School in 1972. After conducting research at the National Institutes of Health, he completed pediatric and pediatric hematology-oncology training at Boston Children’s Hospital and Dana-Farber. He joined the Harvard faculty in 1978 and went on to become one of the leading researchers in blood-cell development and human genetics.
One of the most important areas of Dr. Orkin’s career has been understanding how the body controls fetal and adult hemoglobin. His research helped reveal the molecular mechanisms responsible for switching from fetal hemoglobin to adult hemoglobin after birth. This discovery eventually identified important therapeutic opportunities for diseases such as sickle cell disease and beta-thalassemia.
His work has had particularly significant implications for gene-editing medicine. Research from Dr. Orkin’s laboratory helped identify the role of the BCL11A pathway in controlling fetal hemoglobin. Scientists were subsequently able to use this biological knowledge to develop strategies that reactivate fetal hemoglobin, helping compensate for abnormal adult hemoglobin in patients with serious blood disorders.
In 2026, Dr. Orkin received the prestigious Breakthrough Prize in Life Sciences, sharing the honor with NIH researcher Swee Lay Thein. The award recognized their work that helped establish the biological basis for manipulating fetal hemoglobin as a treatment strategy for sickle cell disease and beta-thalassemia.
Dr. Orkin continues to lead research exploring how fetal hemoglobin can be controlled and potentially reactivated using new approaches. His laboratory combines molecular biology, genetics, chemical biology and animal models to investigate treatments for major blood disorders.
Beyond his scientific discoveries, Dr. Orkin has also made mentorship and physician-scientist development an important part of his career. His work demonstrates how fundamental laboratory research can eventually translate into therapies that change patients’ lives.
For Movers and Shakers, Dr. Orkin is a compelling example of American medical innovation. His career illustrates how decades of persistence, scientific curiosity and collaboration can turn a deeper understanding of human biology into new possibilities for patients with previously devastating diseases.
